MTIM
INO icon

Marathon Trading Investment Management’s Inovio Pharmaceuticals INO Stock Holding History

Marathon Trading Investment Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,300
Closed -$421K – 344
2024
Q1 		$421K Buy
+30,300
New +$262K 0.03% 189

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Marathon Trading Investment Management's INO Position: Q2 2024 in Review

Marathon Trading Investment Management sold out of Inovio Pharmaceuticals (INO) in Q2 2024, closing a stake of 30,300 shares — an estimated $421K sold.

Marathon Trading Investment Management first reported a position in INO in Q1 2024 and held it in 1 quarter. The position peaked at $421K in Q1 2024. 96 funds tracked by Wall St. Rank hold INO as of Q2 2024.

  • Marathon Trading Investment Management reported no remaining Inovio Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 30,300 Inovio Pharmaceuticals shares in Q2 2024, an estimated $421K.
  • Marathon Trading Investment Management first reported a position in Inovio Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Marathon Trading Investment Management's Inovio Pharmaceuticals position peaked at $421K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2024.

Based on Marathon Trading Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.